Thalia Therapeutics Income Statement

Financials in millions GBP. Fiscal year is January - December.

Millions GBP. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	7.26	7.28	0	-	-
Revenue Growth (YoY)	-0.25%	372762.26%	-	-	-
Gross Profit	0.01	0.01	0	-	-
Selling, General & Admin	1.02	0.84	0.72	0.62	0.66
Research & Development	0.21	0.39	0.62	0.58	1.18
Other Operating Expenses	-0.06	-	0.09	-	-
Total Operating Expenses	1.17	1.23	1.43	1.19	1.84
Operating Income	-1.17	-1.22	-1.42	-1.19	-1.84
Total Non-Operating Income (Expense)	-	-	-	0	0
Pretax Income	-1.17	-1.22	-1.42	-1.19	-1.84
Provision for Income Taxes	0.04	-0.1	-0.15	-0.16	-0.3
Net Income	-1.21	-1.12	-1.28	-1.03	-1.54
Minority Interest in Earnings	-0	-0.06	-0.01	-	-
Net Income to Common	-1.21	-1.06	-1.27	-1.03	-1.54
Net Income Growth	-	-	-	-	-
Shares Outstanding (Basic)	724	340	243	186	181
Shares Outstanding (Diluted)	724	341	243	186	181
Shares Change (YoY)	112.51%	40.34%	30.29%	2.95%	32.85%
EPS (Basic)	-0.00	-0.00	-0.01	-0.01	-0.01
EPS (Diluted)	-0.00	-0.00	-0.01	-0.01	-0.01
EPS Growth	-	-	-	-	-
Free Cash Flow	-1.16	-0.97	-1.21	-0.83	-1.77
Free Cash Flow Growth	-	-	-	-	-
Free Cash Flow Per Share	-0.00	-0.00	-0.00	-0.00	-0.01
Gross Margin	0.10%	0.10%	100.00%	-	-
Operating Margin	-16.04%	-16.77%	-72943.90%	-	-
Profit Margin	-16.63%	-15.38%	-65375.20%	-	-
FCF Margin	-15.99%	-13.34%	-61909.80%	-	-
EBITDA	-1.17	-1.22	-1.42	-1.19	-1.84
EBIT	-1.17	-1.22	-1.42	-1.19	-1.84
EBIT Margin	-16.04%	-16.77%	-72943.90%	-	-
Effective Tax Rate	-3.69%	8.28%	10.38%	13.74%	16.19%